Chronic opioid exposure differentially modulates oxycodone self-administration in male and female rats.


Journal

Addiction biology
ISSN: 1369-1600
Titre abrégé: Addict Biol
Pays: United States
ID NLM: 9604935

Informations de publication

Date de publication:
05 2021
Historique:
revised: 20 08 2020
received: 30 05 2020
accepted: 20 09 2020
pubmed: 21 10 2020
medline: 3 11 2021
entrez: 20 10 2020
Statut: ppublish

Résumé

Withdrawal from opioid painkillers can produce short-lived physical symptoms and protracted psychological symptoms including anxiety and depressive-like states that often lead to opioid misuse and opioid use disorder (OUD). Studies testing the hypothesis that opioid withdrawal potentiates the reinforcing effects of opioid self-administration (SA) are largely inconclusive and have focused on males. Although some clinical evidence indicates that women are more likely than men to misuse opioids to self-medicate, preclinical studies in both sexes are lacking. Based on clinical reports, we hypothesized that withdrawal from escalating-dose morphine injections that approximates a prescription painkiller regimen would lead to increased oxycodone SA to a greater extent in female compared to male rats. After escalating-dose morphine (5-30 mg/kg or vehicle, twice/day for 12 days), rats underwent a 2-week abstinence period during which withdrawal signs were measured. The impact of this treatment was assessed on oxycodone SA acquisition, maintenance, dose response, and progressive ratio responding, with additional analyses to compare sexes. We found that both sexes expressed somatic withdrawal, whereas only males demonstrated hyperalgesia in the warm water tail flick assay. During SA acquisition, males with prior morphine exposure took significantly more oxycodone than females. Finally, females with prior morphine exposure demonstrated the lowest motivation to SA oxycodone in the progressive ratio test. Contrary to our initial hypothesis, our findings suggest that prior opioid exposure increases vulnerability to initiate misuse more in males and decreases the reinforcing efficacy of oxycodone in females.

Identifiants

pubmed: 33078503
doi: 10.1111/adb.12973
pmc: PMC8129895
mid: NIHMS1702304
doi:

Substances chimiques

Narcotics 0
Morphine 76I7G6D29C
Oxycodone CD35PMG570

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e12973

Subventions

Organisme : NIDA NIH HHS
ID : R01 DA045000
Pays : United States

Informations de copyright

© 2020 The Authors. Addiction Biology published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.

Références

Drug Alcohol Depend. 2006 Jun;83 Suppl 1:S4-7
pubmed: 16563663
J Neurosci. 1996 Mar 1;16(5):1957-63
pubmed: 8774462
Neuropsychopharmacology. 2004 May;29(5):929-42
pubmed: 14735136
Neuropsychopharmacology. 2003 Nov;28(11):1960-72
pubmed: 12915862
J Neurosci. 2006 Jun 14;26(24):6450-7
pubmed: 16775132
Front Pharmacol. 2014 May 27;5:116
pubmed: 24904419
Physiol Behav. 2002 Jul;76(3):365-77
pubmed: 12117573
Brain Res. 2019 Mar 1;1706:75-85
pubmed: 30391476
Psychopharmacology (Berl). 1999 May;144(1):77-82
pubmed: 10379627
Int J Neuropsychopharmacol. 2019 Nov 1;22(11):735-745
pubmed: 31613314
Mil Med. 2013 Feb;178(2):180-95
pubmed: 23495464
J Neurosci. 2008 Dec 24;28(52):14007-17
pubmed: 19109484
Behav Brain Res. 2006 Jun 3;170(1):110-8
pubmed: 16580078
Clin Pharmacol Ther. 2006 May;79(5):461-79
pubmed: 16678548
Prog Neuropsychopharmacol Biol Psychiatry. 2007 Nov 15;31(8):1614-24
pubmed: 17888555
Science. 1991 Jan 4;251(4989):85-7
pubmed: 1824728
J Pharmacol Exp Ther. 2008 Sep;326(3):920-9
pubmed: 18515643
Arch Intern Med. 1966 Oct;118(4):304-9
pubmed: 4162686
J Subst Abuse Treat. 2013 Jul;45(1):38-43
pubmed: 23313145
Psychopharmacology (Berl). 1992;108(1-2):79-84
pubmed: 1410149
Exp Clin Psychopharmacol. 2004 Aug;12(3):163-72
pubmed: 15301633
Anesthesiology. 2010 Jan;112(1):181-8
pubmed: 19996949
Addict Biol. 2021 May;26(3):e12973
pubmed: 33078503
J Pain Symptom Manage. 2005 May;29(5 Suppl):S47-56
pubmed: 15907646
J Neurosci. 2016 May 25;36(21):5748-62
pubmed: 27225765
Neuropsychopharmacology. 2014 Jan;39(2):254-62
pubmed: 24121188
Pharmacol Biochem Behav. 2002 May;72(1-2):313-8
pubmed: 11900802
Psychiatr Clin North Am. 1986 Sep;9(3):413-25
pubmed: 3534813
J Subst Abuse Treat. 2015 Jan;48(1):1-7
pubmed: 25239857
Addict Behav. 2010 Nov;35(11):1001-7
pubmed: 20598809
Pharmacol Biochem Behav. 2003 May;75(2):349-54
pubmed: 12873626
Pharmacol Biochem Behav. 2006 Jan;83(1):100-8
pubmed: 16434089
Drug Alcohol Depend. 1998 Jun-Jul;51(1-2):23-47
pubmed: 9716928
Biol Sex Differ. 2012 Jun 07;3(1):14
pubmed: 22676718
Neuropsychopharmacology. 2016 Jan;41(1):383-4
pubmed: 26657961
Psychol Rev. 1974 Mar;81(2):119-45
pubmed: 4817611
PLoS One. 2011 Apr 07;6(4):e17870
pubmed: 21490964
J Neurosci. 2006 Apr 5;26(14):3855-63
pubmed: 16597740
Eur J Pharmacol. 1989 Feb 14;161(1):19-25
pubmed: 2721546
Nature. 1996 Oct 31;383(6603):819-23
pubmed: 8893006
Neuroscience. 2016 Dec 3;338:160-182
pubmed: 27346146
Exp Clin Psychopharmacol. 2006 Feb;14(1):34-41
pubmed: 16503703
Alcohol Alcohol. 2009 Nov-Dec;44(6):575-85
pubmed: 19793926
Psychopharmacology (Berl). 2012 Feb;219(4):991-8
pubmed: 21833504
J Pharmacol Exp Ther. 1995 Feb;272(2):781-5
pubmed: 7853194
Drug Alcohol Depend. 2020 Feb 1;207:107819
pubmed: 31918232
Psychopharmacology (Berl). 2017 Mar;234(6):977-987
pubmed: 28127624
Pharmacol Biochem Behav. 1997 Jul;57(3):441-7
pubmed: 9218268
Trends Pharmacol Sci. 1990 Feb;11(2):77-81
pubmed: 2156364
Annu Rev Psychol. 2008;59:29-53
pubmed: 18154498
J Neurochem. 1992 May;58(5):1620-5
pubmed: 1313849

Auteurs

Maria Mavrikaki (M)

Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, Massachusetts, USA.

Tania Lintz (T)

Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, Massachusetts, USA.

Nick Constantino (N)

Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, Massachusetts, USA.

Sarah Page (S)

Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, Massachusetts, USA.

Elena Chartoff (E)

Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, Massachusetts, USA.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH